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Aim. To find candidate tumor suppressor genes among metallothioneins for clear cell renal cell carcinoma. 
Methods. Analysis of the microarray data, quantitative PCR. Results. We found three genes encoding metal-
lothioneines that showed reduced expression in different types of renal tumors, using protocol of the cross-
platform meta-analysis of microarray data with normalization on several reference genes. Decreased expres-
sion of the MT1G, MT1F, and MT1H genes in clear cell renal cell carcinoma was confirmed by qPCR. 
Conclusions. The MT1G, MT1F and MT1H genes as well as may be considered as the candidate tumor sup-
pressor genes for ccRCC.
K e y w o r d s: metallothionein, renal tumors, candidate tumor suppressor gene, microarrays.
Introduction
Nowadays cancer is one of the major causes of death. 
Tumorigenesis is a result of disturbance of genome 
function under the influence of various factors. One 
of the reasons of appearance origin of the malignant 
cells is inactivation of the tumor suppressor genes by 
methylation, mutations or deletions. Metallothioneins 
are the small proteins, consisting of 61–68 amino 
acid residues and characterized by a high content of 
cysteine and complete absence of aromatic amino ac-
ids [1]. The genes of a metallothionein family are lo-
cated on the 16q13 locus and this family consists of 
10 functional isoforms [2]. There are four major 
genes among them: MT1 (seven functional genes 
MT1A, -1B, -1E, -1F, -1G, -1H, -1X), MT2A, MT3, 
and MT4. [The] MT1 and MT2A genes are expressed 
in different cell types; MT3 is expressed only in the 
brain and sexual organs, and MT4 only in stratified 
squamous epithelium in skin and tongue. Earlier it 
has been shown that only the MT1 and MT2A genes 
are involved in the regulation of embryogenesis as 
well as in other processes, such as interaction with 
metals, oxidative stress, signaling of cytokine and 
glucocorticoid hormones [3]. The function and ex-
pression of the MT family genes in human tumors 
were investigated thoroughly, however, the published 
results are often controversial for different types of 
tumors; so, the real contribution of these important 
molecules to the malignant cell transformation has 
not been elucidated yet. Overexpression of the MT 
family genes was reported for some tumors, such as 
melanoma, breast and lung cancers. In contrast, ex-
pression of MT family genes is decreased upon can-
cerogenesis in other types of tumors, such as colon 
and hepatocellular carcinomas [3]. The regulation of 
expression of the MT family genes occurs through 
methylation of the promoter region. The inactivation 
by methylation for the MT1H gene was demonstrated 
for the malignant tumors of prostate and liver [4]; for 
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the MT1G gene - in hepatoblastoma [5], thyroid tu-
mors of different histological types [3], and in the 
patients with squamous cell cancer of the esopha-
gus [6] as well. The methylation of promotor region 
of the MT1G gene also was shown, especially for pri-
mary renal cell carcinoma; however, the expression 
has not been studied, [7]. It was demonstrated that the 
MT1F expression was lower in the colon tumors due 
to the loss of heterozygosity [8, 9]. Notably, the level 
of MT1F gene expression in primary renal cell carci-
noma remained unchanged [10].
Using the protocol of the cross-platform meta-
analysis of microarray data with normalization on 
several reference genes, we found three isoforms of 
the MT1 gene, the expression of which is reduced in 
various types of the renal tumors. Expression of the 
MT1G, MT1F, and MT1H genes in clear cell renal 
cell carcinomas (ccRCC) was examined by qPCR. 
Our data suggest that the MT1G, MT1F, and MT1H 
genes may act as oncosuppressors in ccRCC.
Materials and Methods
Analysis of microarray and search [for] MT 
genes with low expression
We performed the online search for Series and 
DataSet files, using http://www.ncbi.nlm.nih.gov/geo 
and the following keywords: clear cell renal cell car-
cinoma, normal human kidney, chromophil renal cell 
carcinoma, chromophobe renal cell carcinoma, and 
oncocytoma. Series and DataSet files contain records 
of the data sets, which were studied by the common 
platform. The platform is a description of the micro-
chip. Record describes the type of tissue, the condi-
tions under which a single sample has been pro-
cessed, manipulated incurred, and measurement re-
sults for that sample. The series [file] brings together 
a group of similar samples and provides description 
of the study. Files “Series” are provided by the au-
thors of the study and GEO personnel transform them 
into a DataSet (GDSxxx). DataSet files contain infor-
mation on expression levels obtained experimentally 
on the microchip. Each DataSet file contains the 
available data for a set of samples, and it is possible 
to compare them biologically and statistically within 
a single file. Files Series contain metadata translated 
into a format similar to the files DataSet, using pack-
age GEOquery for R (http://bioconductor.org/pack-
ages/1.8/bioc/html/GEOquery.html). Due to the fact 
that individual DataSet files were created by different 
authors, using different microarrays and equipment, 
it is impossible to compare the data from different 
files without normalization. To compare different 
files we have used two reference genes for normal-
ization. For this, the expression value for each sample 
was divided by the geometric mean value of the PPIA 
and TBP expression in the same sample [11]. Upon 
the analysis, the average value for expression of each 
gene was calculated, using scripts written in Perl, for 
tumors and normal tissue.
Total RNA isolation
20 pairs of tumor samples and normal adjacent tis-
sues were obtained from the National Cancer Institute 
of the National Academy of Medical Sciences. All 
tissue samples were diagnosed as the same histologi-
cal type – ccRCC, which was classified, according to 
the American Joint Committee on Cancer (TNM) and 
nuclear atypia by Furman (Table 1). Total RNA was 
isolated, using RNeasy mini Kit (Qiagen, Valencia, 
CA), according to the manufacturer instruction. The 
quality of the isolated RNA was assessed by electro-
phoresis, using 1 % agarose gels.
cDNA Synthesis
1 µg of the total RNA was treated with the DNA-se 
for 30 min at 37˚C, and the reaction was inhibited 
with 25 mM EDTA (Thermo Scientific, USA). CDNA 
synthesis was performed, using the Oligo (dT) – prim-
ers (a final volume of reaction was 20 µl), and the 
First Strand cDNA Synthesis Kit (Thermo Scientific, 
USA), according to the manufacturer protocols.
Quantitative PCR
The real time PCR (qPCR) reactions were carried 
[out], using a mixture that contained 1 x reaction 
mix SYBR Green (Thermo Scientific, USA), includ-
ing polymerase, dNTPs, 0.4 µM of each primer and 
460
V. I. Rymar, L. Lototskaya, O. G. Kondratov et al.
500 ng of cDNA. [The] Reaction conditions were as 
follows: 95˚C – 10 min, 40 cycles 95˚C – 15 s, 
60˚C – 20 s, 72˚C – 30 s. A reaction volume was 
25 µl. CFX96 BioRad machine was used. The qual-
ity of the PCR product was checked by the analysis 
of melting curves. Reactions for different samples 
were normalized, using the amplification reference 
gene TBP (encoding TATA box binding protein), 
which shows the constant expression in different 
samples. The relative fold change was calculated, 
using the ΔΔCt method. The efficiency of amplifica-
tion was calculated by the R-package software, ver-
sion 2.12.1 [12]. The primers were selected, using 
OligoAnalyzer 3.1 software. For [the] MT1G ampli-
fication the following primers were used: direct (5’- 
GCTCCTGTGCCGCTGGTGT -3 ‘and reverse (5’- 
GCAGCAGCTGCACTTCTCCGAT -3’), product 
size was 167 bp. For [the] MT1H amplification – di-
rect (5’- CCAACTGCTCCTGCGAGGCTG -3 ‘and 
reverse (5’- GCCCAGGGGGCAACAGGAG -3 ‘), 
product size 113 bp. For [the] MT1F amplification – 
direct (5’- CTCCTGCACCTGCGCTGGT -3’ and 
reverse (5’- TCTGACGCCCCTTTGCAAACA 
-3 ‘), the size of the product – 132 bp.
Statistical analysis
 A comparison between the groups was done by us-
ing the independent samples t test. A value of P<0.05 
was considered as statistically significant.
Results and Discussion
7 files that contain the data of gene expression in tu-
mors and normal kidney tissue were found in the 
GEO database. In total, there were 9 ccRCC of stage 
1 by Furman, 11 ccRCC of stage 2, 14 ccRCC sam-
ples of stage 3 as well as 55 chromophyle and 14 
chromophobe kidney tumors, 14 oncocytomas, and 
23 samples of normal tissue. The genes were select-
ed that showed a decrease in the expression by more 
than 5 fold (P <0.05), compared with the normal tis-
sue. Then the search for the MT family genes was 
performed, looking for the genes with reduced ex-
pression in all six tumor types. Three such genes – 
MT1G, MT1H, and MT1F – were found. There are 
the literature data showing changes in their expres-
sion during the development of various cancers, that 
is why we assumed that these genes might be sup-
pressors for kidney tumors. For each patient, the tu-
mor and normal tissue samples were paired. The 
normal tissue control samples were represented by 
the adjacent to the tumor but not malignantly trans-
formed kidney tissues. To study the gene expression 
pattern, 20 pairs of samples (tumor/norma) from the 
renal carcinomas of varying degrees of malignancy 
were used (Table 1).
MT1G, metallothionein 1G
The MT1G expression decreased significantly 
(P=0.0047) in ccRCC samples, compared with nor-
mal tissue (Fig. 1), that is in line with the results for 
other types of tumors [3, 10, 13–15]. The main mech-
anism of the regulation of MT1G gene expression is 
associated with promoter hyper-methylation. Hyper-
Table 1.
N TNM Stage
1 T1bNxM0 I
2 T1bNxM0 I
3 T1aNxM0 I
4 T2aNxM0 II
5 T1aNxM0 I
6 T1aNxM0 I
7 T4NxMo IV
8 T1bNxMo I
9 T3NxMo III
10 T1aNxMo I
11 T1aNxMo I
12 T2aNxMo II
13 T1aNxMo I
14 T1aNxMo I
15 T2aNxMo II
16 T1bNxM0 I
17 T1aNxM0 I
18 T1bNxM0 I
19 T1aNxMo I
20 T2aNxM1 II
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methylation of promoter region of the MT1G was ob-
served in hepatoblastoma, hepatocellular carcinoma, 
thyroid tumors of different histological types, esoph-
ageal squamous cell cancer and prostate tumors [3, 5, 
6, 13, 16]. The rate of hyper-methylation of MT1G 
promoter showed correlation with poor prognosis for 
patients with hepatoblastomas. So, hyper-methyla-
tion of the MT1G promoter might be useful as a prog-
nostic factor for the course of disease; moreover, de-
methylation of this gene in hepatoblastoma might 
suggest the positive effect in the treatment [5]. The 
level of MT1G promoter methylation in prostate tu-
mors correlates with tumor progression stage, but not 
with stage by Gleason. The MT1G promoter hyper-
methylation was observed more frequently in pros-
tate tumors that spread beyond the prostate capsule. 
So, the MT1G promoter methylation is associated 
with the aggressive prostate cancer [16].
The qPCR results showed that the MT1G gene ex-
pression also reduced in ccRCC compared with nor-
mal tissue. Thus, the MT1G gene may be a potential 
tumor suppressor for ccRCC. Moreover, it might be 
also used as a prognostic tumor marker.
MT1F, metallothionein 1F
Expression of the MT1F gene was significantly low-
er (P = 0.00077) in ccRCC compared with normal 
tissue (Fig. 2). Only in tumor number 17, there was 
a slight increase in the expression.
Earlier a significant reduction of the MT1F gene 
expression has been demonstrated only for colon tu-
mors and hepatocellular carcinomas [8, 17]. 
Overexpression of MT1F in the RKO colon cancer 
cell line resulted in promotion of apoptosis and also 
prevented cell migration, invasion and adhesion in vi-
tro. A reduced expression of the MT1F gene in colon 
tumors was observed, due to loss of heterozygosity (p 
= 0.001), whereas the methylation of CpG islands in 
the promoter region of the MT1F gene was observed 
only in colon cancer cell lines RKO and LoVo. So, 
MT1F is a potential tumor suppressor of colon can-
cers, which inhibited mainly, due to loss of heterozy-
gosity [8]. When the HepG2 cell line was transfected 
with [an] expression vector pCMV-MT1F, the cells 
proliferated slowlier, compared with the control line 
HepG2. It was also reported that the MT1F expression 
at the mRNA and protein levels is significantly higher 
Fig. 1. Relative mRNA level of MT1G gene in ccRCC compared to normal tissue, assessed by qPCR.
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in the normal tissue, than in hepatocellular carcino-
mas. Hence, MT1F may play an important role in 
gene therapy of hepatocellular carcinoma [17]. Earlier 
it has been shown that the MT1F expression levels in 
primary renal cell carcinoma remain unchanged in 
comparison with the control group [10].
According to the obtained data (microarray analy-
sis with GEO and qPCR), expression of the MT1F 
gene significantly reduced in ccRCC. As the MT1F 
gene is the potential suppressor for colon tumors and 
hepatocellular carcinomas, and therewith it showed 
reduced expression in tumors of the kidneys, we 
suppose that the MT1F gene is the putative tumor 
suppressor for ccRCC and might be used as the tu-
mor progression marker.
MT1H, metallothionein 1H
Expression of the MT1H gene significantly (P = 
0.004) reduced in ccRCC compared with normal tis-
sue (Fig. 3).
The main mechanism of the gene expression regu-
lation is associated with the MT1H promoter hyper-
methylation. So, inter-connection between the pro-
moter methylation and the gene MT1H expression 
was shown in prostate and liver tumors. The low 
MT1H expression was also associated with poor 
clinical outcomes for patients with both, prostate and 
liver cancers. De-methylation of promoter in cell 
lines in vitro restores the MT1H gene expression, 
leading to a slower cell proliferation, suppression of 
colony formation, and reduced ability of cells to mi-
grate [4]. It was shown that MT1H can interact with 
euchromatin histone methyltransferase 1 (EHMT1) 
enhancing its methyltransferase activity on histone 
3. Inhibition of the interaction between EHMT1 and 
MT1H leads to inactivation of the tumor suppression 
by MT1H [4]. As has been shown earlier, the primary 
renal cell carcinoma biopsy specimens had a lower 
expression of the MT1H transcripts than the pooled 
normal human controls [10].
Fig. 2. Relative mRNA level of MT1F gene in ccRCC compared to normal tissue, assessed by qPCR.
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Our qPCR data of the MT1H gene expression in 
ccRCC type in comparison with normal tissue show 
the same trend. Since the MT1H functions as the 
growth suppressor for prostate and liver tumors, and 
therewith shows a lower expression in the primary 
renal cell carcinoma, we suppose that this gene is the 
tumor growth suppressor for ccRCC. The MT1H 
gene might be used also as a tumor marker.
Conclusions
Using the protocol of the cross-platform meta-analy-
sis of microarray data with normalization on several 
reference genes we have found three genes of the 
MT family that showed reduced expression in differ-
ent types of renal tumors. The expression of the 
MT1G, MT1F, and MT1H genes in ccRCC was also 
studied by qPCR. Taking into consideration that the 
MT1G gene is a potential suppressor for different 
types of tumors, the MT1F gene is a potential sup-
pressor for colon tumors and hepatocellular carci-
noma, and the MT1H gene is a potential suppressor 
for prostate and liver cancers, we suppose that these 
genes are potential suppressors for ccRCC and can 
be used as the tumor markers.
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Зміна рівня експресії металотіонеїнів при світло-
клітинній карциномі нирок
В. І. Римар, Л. В. Лотоцкая, О. Г. Кондратов, 
Е. О. Стаховський, О. А. Кононенко, В. І. Кашуба
Мета. Пошук потенційних генів-супресорів серед металотіо-
неїнів при розвитку світло-клітинної карциноми нирок. 
Методи. Біоінформатичний аналіз баз даних мікрочіпів, кіль-
кісна ПЛР. Результати. Використовуючи біоінформатичні ме-
тоди порівняння різних баз даних мікрочипів із застосуванням 
кросплатформенної нормалізації по декількох референтних 
генах, нами було знайдено три гени з родини металотіонеїнів, 
що показують знижену експресію у різних типах пухлин ни-
рок. Зниження експресії генів МТ1G, MT1F та MT1H в зразках 
світлоклітинної карциноми нирок було продемонстровано ме-
тодом кількісної ПЛР. Висновки. Гени МТ1G, MT1F та MT1H 
є потенційними супресорами росту пухлин нирок.
К л юч ов і  с л ов а: металотіонеїни, пухлини нирок, потен-
ційний ген-супресор росту пухлин, мікрочіпи
Изменение уровня экспрессии генов металлотионеинов 
при светло-клеточной карциноме почек
В. И. Рымар, Л. В. Лотоцкая, А. Г. Кондратов, 
Э. А. Стаховский, А. А. Кононенко, В. И. Кашуба
Цель. Поиск потенциальных генов-супрессоров светло-кле-
точной карциномы почек среди металлотионеинов. Методы. 
Анализ результатов микрочипов, выделение тотальной РНК, 
количественная ПЦР. Результаты. Используя метод сравнения 
результатов микрочипов с применением кроссплатформенной 
нормализации по нескольким референтным генам, нами были 
найдены три гена семейства металлотионеинов с пониженной 
экспрессией в различных типах опухолей почек. Снижение 
экспрессии генов МТ1G, MT1F и MT1H в светлоклеточной 
карциноме почек было продемонстрировано методом количе-
ственной ПЦР. Выводы. Гены МТ1G, MT1F и MT1H могут 
рассматриваться как потенциальные супрессоры роста опухо-
лей почек.
К л юч е в ы е  с л ов а: металлотионеин, опухоли почек, по-
тен циальный ген-супрессор.
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